Although the pathophysiology and molecular basis of sickle cell disease (SCD) were described more than half a century ago, an effective and safe therapy is not yet available. This may be explained by the lack of a suitable high-throughput technique that allows rapid screening of thousands of compounds for their antisickling effect. The authors have thus developed a novel high-throughput screening (HTS) assay based on detecting the ability of red blood cells (RBC) to traverse a column of tightly packed Sephacryl chromatography beads. When deoxygenated, sickle RBC are rigid and remain on the top of the column. However, when deoxygenated and treated with an effective antisickling agent, erythrocytes move through the Sephacryl media and produce a red dot on the bottom of the assay tubes. This approach has been adapted to wells in a 384-well microplate. Results can be obtained by optical scanning: The size of the red dot is proportional to the antisickling effect of the test molecule. The new assay is simple, inexpensive, reproducible, requires no special reagents, and should be readily adaptable to robotic HTS systems. It has the potential to identify novel drug candidates, allowing the development of new therapeutic options for individuals affected with SCD. (Journal of Biomolecular Screening. 2009:330-336) Key words: sickle cell disease, high-throughput screening, cell-based assay, assay development, drug discovery and has identified logical targets for pharmacological intervention aimed at reducing HbS polymerization and thus RBC sickling. To date, a limited number of drug candidates have been proposed, yet none of these agents are suitable for clinical use because of their low potency and/or high toxicity.
and has identified logical targets for pharmacological intervention aimed at reducing HbS polymerization and thus RBC sickling. To date, a limited number of drug candidates have been proposed, yet none of these agents are suitable for clinical use because of their low potency and/or high toxicity. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] It is only recently that the chemotherapeutic drug hydroxyurea (HU) has been shown to greatly reduce the frequency and severity of SCD complications for many patients. 4, 6 Although it is the most effective treatment option available to date, its significant toxicity raises questions about its widespread and longterm clinical use.
Earlier studies focusing on the pharmacologic therapy of SCD have typically evaluated 1 compound or a small series of structurally related molecules at a time. However, the identification of new drug candidates warrants the screening of a library containing tens of thousands of different molecules, a procedure referred to as high-throughput screening (HTS). 15, 16 Existing techniques are not necessarily well suited for automated HTS systems, inasmuch as they lack basic characteristics necessary to effectively screen for novel antisickling agents (i.e., high assay reliability and reproducibility, simple endpoints, short cycle times, and low per-sample cost). Therefore, our goal was to develop a simple, cell-based, HTS-compatible assay to screen for compounds with the ability to reduce or prevent RBC sickling under deoxygenated conditions and therefore the ability to inhibit the vaso-occlusive process. Our efforts were focused on developing the methodology to screen
INTRODUCTION

S
ickle cell disease (SCD) is one of the most common genetic disorders worldwide, with about 1 in 600 African American newborns affected. 1 The disease results from a single amino acid substitution (i.e., valine for glutamic acid) in the beta globin chain; this substitution yields the abnormal hemoglobin S (HbS) rather than the normal hemoglobin A (HbA). HbS polymerizes and gels under low-oxygen tensions, causing red blood cells (RBC) to become rigid and distorted into characteristic elongated or spiculated shapes. Patients homozygous for the disease suffer severe complications, such as repeated pain crises, acute chest syndrome, and stroke, owing to the obstruction of small vessels in the microcirculation by rigid, distorted RBC (i.e., vaso-occlusion).
The molecular basis of SCD was discovered more than half a century ago, 2 raising hopes that an effective drug treatment would soon follow. Intense research since that time has helped to better understand the basic pathophysiology of the disease for molecules that act directly on circulating RBC but without restriction to specific physicochemical targets or mechanisms of action. The present article describes the principle of this novel assay and provides data on its sensitivity and reproducibility.
MATERIALS AND METHODS
Patient samples
Blood samples were obtained from 36 randomly selected adult patients attending the outpatient sickle cell clinic at the LAC+USC Medical Center. Six patients were later excluded from the study, as 4 patients had received recent transfusion therapy and 2 patients had HbS/HbC disease. The remaining 30 participants were homozygous (i.e., HbSS) in steady-state condition and had not received transfusion within at least 90 days prior to enrollment. After obtaining informed consent, 5 ml of venous blood was collected via sterile venepuncture into a vacuum tube containing EDTA (1.5 mg/ml). To serve as control, 5 ml of peripheral blood was also collected from healthy adult volunteers with the normal HbA phenotype. Complete blood counts were determined using an automated hematology analyzer (Micros; Horiba-ABX, Irvine, CA). Note that as a convenience, RBC from SCD patients are designated as sRBC and those from controls as aRBC. The study was approved by the local Ethics Committee and was performed according to the Declaration of Helsinki.
Assay preparation
All blood samples were centrifuged at 1000g for 6 min, and the plasma and buffy coat were discarded. RBC were washed with isotonic phosphate-buffered saline (PBS, pH = 7.4, 270 mOsm/kg H 2 O) and resuspended in PBS at hematocrits (Hct) ranging from 2% to 50%. RBC suspensions were either maintained at room air pO 2 (∼150 mm Hg) and 37 °C, or were incubated at 37 °C in a humidified 95% N 2 + 5% CO 2 atmosphere to reduce pO 2 to approximately 40 mm Hg, a physiological value for the microcirculation and postcapillary venules. Sephacryl S-500 chromatography beads (Sigma-Aldrich, St. Louis, MO) were washed 3 times in PBS, and following the final wash, deoxygenated PBS was used to prepare a 50% v/v suspension of the beads.
Sickling assays
Microtube assay. For the initial evaluations, 40 mm long × 4 mm diameter, 250-µl clear polypropylene tubes were filled with 125 µl of the deoxygenated Sephacryl S-500 suspension; the tubes were capped and then centrifuged at 3000g for 5 min to form a packed column of the beads. Three-microliter aliquots of oxygenated sRBC, deoxygenated sRBC, or aRBC were pipetted into the tubes directly above the gel column and centrifuged at 380g for 3 min. The oxygenated sRBC and aRBC served as positive controls for this series of experiments.
Results were obtained visually by observing the bottom of the polypropylene tubes: A red pellet indicated that the test erythrocytes passed through the column, but only a white dot (i.e., the color of the Sephacryl S-500 beads) could be observed if no cells reached the bottom of the tube.
Microplate test. Following the initial validation of the concept, the assay was adapted to a multiwell format appropriate for HTS. The wells of an optically transparent, polypropylene 384-well PCR plate (conical-shaped bottom; Sorenson Bioscience Inc., Salt Lake City, UT) were filled with deoxygenated Sephacryl S-500/PBS suspension, sealed with a gas-impermeable film, and centrifuged at 3000g for 5 min to pack the bead column. Two microliters of a 2% to 50% Hct oxygenated sRBC, deoxygenated sRBC, or aRBC suspension were added to each well. The plate was resealed with the oxygen-impermeable adhesive film and then centrifuged at 380g for 3 min in a swinging bucket rotor designed for such plates.
Results were documented by imaging the plates from below using a commercially available flatbed scanner at 300 dpi in the 24-bit RGB color format. If the test erythrocytes passed through the column, they formed a pellet at the base of the well visible as a distinct red dot, whereas if the RBC became trapped in the top of the column, the base of the well remained bright white. Quantitative data were obtained by averaging blue channel data over a precisely defined, 112-pixel circular area at the base of each well using simple image analysis routines created with Visual Basic; the blue channel was selected because the blue spectra is absorbed most strongly by hemoglobin. As scanned images represent reflectance, the intensity of blue light absorbance by RBC at the bottom of the wells equals (255 -blue intensity) based on the 24-bit RGB color scheme.
To evaluate the sensitivity of the assay to biological variability in sRBC properties, we initially tested samples from all 36 randomly selected patients; as described above, 6 patients were later excluded from further analysis. For the remaining SCD subjects, we measured the following parameters: mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), and percentage hemoglobin F (HbF) as determined by high-performance liquid chromatography (HPLC) and the use of hydroxyurea.
To test the reproducibility of the novel assay, 78 wells of the PCR plate were filled with the Sephacryl S-500 suspension. After centrifugation at 3000g for 5 min, 2 µl of 5% Hct oxygenated sRBC, deoxygenated sRBC, or aRBC suspension were transferred into 26 wells per suspension. Plates were centrifuged at 380g for 3 min, and results were obtained using a flatbed scanner as described above. The standardized screening window (Z′ factor) was also calculated to statistically test the suitability of this novel method for HTS applications. 17 Our novel assay system uses intact sRBC; however, access to venous blood from SCD patients might not be readily available at all HTS facilities. Thus, temporary sample storage and transport might be necessary before the screening process can be initiated. To test how long sRBC can be stored without significant loss of assay reproducibility or sensitivity, cells were washed twice in PBS, resuspended at 50% Hct in an RBC storage medium (i.e., PBS supplemented with 5 mM glucose, 1 mM adenine, and 10 mM inosine), and stored at 4 °C. The performance of the assay was tested after 1 h (day 0) and on days 1, 2, 4, 7, 10, 14, 21, and 30.
Assay performance
The wide range of test substances that can be screened using our assay may have 1) no antisickling effects at all, 2) a desirable antisickling effect, or 3) adverse effects on either the RBC or the assay components. To examine the possible outcomes, a set of compounds with very different effects on the erythrocytes were compared. sRBC were incubated at 5% Hct and 37 °C for 60 min in the presence of the test agent ( Table 1) . Following the incubation period, all samples were deoxygenated to an approximate pO 2 value of 40 mm Hg and were tested according to the microplate method. In addition, dose-response curves were obtained for agents with known antisickling properties: aspartame (3.125, 6.25, 12.5, and 25 mM), phenylalanine (2.5, 5, 10, and 20 mM), phenylalanine methyl ester (2.5, 5, 10, and 20 mM), and potassium cyanate (3.125, 6.25, 12.5, and 25 mM). Antisickling efficacy was calculated by counting the number of red pixels detected over a precisely defined, 112-pixel circular area at the base of a well containing a test agent and comparing this value to the maximum of 112 red pixels for untreated aRBC.
RESULTS
Sickling assays
When tested in the microtube system, deoxygenated sRBC became trapped within the top 1 to 2 mm of the Sephacryl S-500 column upon centrifugation, thus creating a red band at the top of the packed beads and leaving the bottom of the test tubes bright white (Fig. 1) . In contrast, oxygenated sRBC passed through the channels between the Sephacryl S-500 beads to form a visible red pellet at the bottom of the polypropylene tubes. As anticipated, aRBC also formed a single pellet at the bottom of the assay tubes, irrespective of the oxygen tension. Mixtures of equal numbers of sRBC and aRBC, simulating the effects of transfusion therapy for SCD patients, formed a single pellet when oxygenated but separated into an upper band and a small pellet when deoxygenated (data not shown).
Varying the hematocrit of the test suspension between 2% and 50% had no effect on the assay outcome: Results were reliable and reproducible over this Hct range. At Hct below 2%, all erythrocytes passed through the column, and when tested at greater than 50% Hct, there was a tendency for RBC to flow between the bead column and the tube wall on the side furthest from the centrifuge axis, thus yielding occasional false-positive results.
Following the initial experiments, the method was adapted to an inexpensive, 384-well PCR plate. The assay readout is illustrated in Figure 2 : normal, aRBC (columns 1 and 2) as well as oxygenated sRBC (columns 4 and 5) passed through the packed Sephacryl column and formed a pellet at the base of the wells, visible as a distinct red dot. In contrast, deoxygenated sRBC (columns 7 and 8) became trapped between the beads during centrifugation, leaving the bottom of the wells bright white. The reproducibility of the assay is also demonstrated in Figure 2 : Visibly identical results were observed in all 26 wells corresponding to a particular test suspension (i.e., aRBC, oxygenated sRBC, or deoxygenated sRBC). To obtain a quantitative assay readout, light intensity data from the flatbed scanner were further analyzed (see the Materials and Method section). Results of the image analysis (Fig. 3) confirmed the visual observations: The 26 wells with oxygenated sRBC and the 26 with deoxygenated sRBC differed markedly in blue light absorbance values and exhibited excellent well-to-well agreement (mean ± SD of 251.0 ± 1.7 for oxygenated, 10.8 ± 3.6 for deoxygenated). The significant difference in readout values for the 2 test conditions is of particular merit in that it provides a wide enough range to allow sensitive evaluation of agents even with modest antisickling effects. For this small data set, the calculated Z′ factor is 0.93, consistent with an assay suitable for HTS.
As the use of human erythrocytes is central to the methodology, it was critical to assess the sensitivity of the assay to interindividual differences in sRBC properties. Thirty of the 36 tested samples, 13 of which were from patients receiving HU therapy, behaved precisely as expected despite the considerable variation in cellular properties: Reliable results were obtained for percentage HbF of less than 1% to 21.2% (average = 7.36%), MCV values of 67 to 106 µm 3 ; MCHC of 30.4 to 37.8 g/dl, and RDW between 5% and 20% (data not shown). Blood from 6 patients did not provide satisfactory results in that deoxygenated control RBC were able to reach the bottom of the wells. Detailed analysis revealed that 4 of the 6 subjects had recently been transfused and that 2 patients had HbS/HbC disease. When testing the shelf life of sRBC, we found that cells may be stored for up to 14 days without affecting the assay readout. After 14 days of storage, changes in cell properties occasionally led to reduced assay sensitivity or reproducibility. Experiments to develop storage media allowing extended sRBC storage are ongoing; however, 2 weeks should allow enough time for sample transfer, initial validation of the test RBC batch, and performance of high-throughput compound screening.
Assay performance
The performance of the assay was tested using a set of compounds with very different effects on erythrocytes ( Table 1) 
FIG. 3.
Reproducibility of oxygenated and deoxygenated wells on a single plate with sRBC from 1 donor; 26 wells were filled with oxygenated and 26 with deoxygenated sample. PCR plates were scanned in color at 300 dpi, and the signal obtained at the blue channel was averaged over a 112-pixel circle for each well. As the image represents reflectance, the absorbance due to the presence of RBC is (255 -blue intensity) for 24-bit RGB color. Mean ± 3 SD is shown for each set of samples.
All wells except wells 1 (aRBC) and 8 (blank) contain sRBC; both oxygenated controls (wells 1 and 2) show red dots on the bottom, whereas the deoxygenated control (well 4) is white, confirming that the sRBC are captured at the top of the bead column (Fig. 4) . As anticipated, 5 20 mM potassium cyanate abolished sickling, leading to a prominent red pellet in well 7. Weaker positive results were observed for phenylalanine, phenylalanine methyl ester, and aspartame (wells 5, 6, and 10), each of which are known to have a modest, but detectable, antisickling effect. 10, 11 Ammonium thiocyanate is not known to have any antisickling effects, and none were observed in the assay (well 9). A clear negative result was obtained for all agents with deleterious effects on RBC (wells 3, 11, 12, and 13), suggesting that compounds that grossly damage RBC will be screened out rather than detected as hits. Similarly, the strong yellow color of trinitrophenol had no affect on the assay performance (well 11). Dose-response curves for compounds with known antisickling effects are shown in Figure 5 . Increasing concentrations of the test agents were gradually more effective in preventing deoxygenation-induced sRBC sickling in the concentration range tested, thus allowing progressively more cells to reach the bottom of the wells, producing an increasing number of red pixels. Note that the results shown in Figure 5 allow estimation of the concentration required to inhibit sickling by one-half of the potential maximum (IC 50 ): 9 mM for aspartame and potassium cyanate, 12 mM for phenylalanine, and, by extrapolation, about 25 mM for phenylalanine methyl ester.
DISCUSSION
Although the underlying molecular defect and the pathophysiology of SCD have been known for many decades, HU represents the only rational pharmacological treatment option today. Despite its general success, a significant number of patients show inadequate response, and concerns remain regarding the long-term safety of this cytotoxic drug. Considering the adverse social and medical aspects of SCD, an effective and safe drug that prevents or alleviates deoxygenation-induced sRBC sickling and thus vasoocclusive complications would have great benefit for thousands of patients in the United States and many more worldwide.
Existing assays aiming to identify novel compounds with antisickling activity are not necessarily well suited for automated HTS systems and have inherent limitations. Current cell-based techniques are complicated, often inaccurate, require sequential rather than parallel measurements, are difficult to automate, and/or have compound endpoints (e.g., analysis of RBC shape change by complex image analysis routines). 5, 18, 19 Cell-free assays using HbS solutions 20, 21 are simpler to perform, faster, and easier to automate. However, such simplification risks generating many false leads, including compounds that cannot pass through the RBC membrane and hence have no cellular uptake, that interact with cellular components other than hemoglobin, or that are rapidly degraded or metabolized by the cell. In addition, cell-free assays will miss other potential targets in the RBC (e.g., membrane-active agents).
The first HTS studies for SCD focused on screening for agents besides HU that are able to stimulate the production of the fetal form of hemoglobin (HbF): HbF tends to inhibit the polymerization of HbS and hence has an antisickling effect. In a recent study, more than 180,000 compounds were screened using modified K562 reporter cells, 8 but the potency for stimulation was associated with severe cytotoxicity. Considering the critical need to develop novel antisickling therapeutics and the disadvantages of readily available screening tests, our goal was to develop a simple, reliable, cell-based, HTS-compatible assay to identify novel antisickling drug candidates that act directly on the RBC without restriction to specific physicochemical targets or mechanisms of action.
As part of the initial experiments, we performed studies to better understand the principle of the assay. Microscopic evaluation of the Sephacryl chromatography media showed that most of the beads had a diameter between 50 and 65 µm, thus in agreement with the nominal value of 25 to 75 µm stated by the manufacturer. The size of the smallest gaps between the tightly packed beads was calculated to be approximately 9 to 10 µm assuming close-packed rigid spheres and thus larger than the 7-to 8-µm undeformed diameter of human erythrocytes. Because even rigid cells would be expected to pass through channels of this size, further studies were initiated to better understand the principle of the bead-based assay. The passage of sRBC and aRBC through a Sephacryl column was examined microscopically using flat glass capillaries (0.3 mm thick × 5 mm wide × 50 mm long) packed with beads. Our observations in this optically accessible simulation of tubes or microplates revealed that sRBC behavior was critically dependent on the cell concentration at the top of the column. At Hct values less than 2%, deoxygenated sRBC passed single file through the interbead channels and were never trapped, even though they were distorted and sickled. When tested at higher Hct, several cells would arrive at a narrow restriction simultaneously. If the cells were deformable, such as aRBC or oxygenated sRBC, they were slowed briefly but then slipped past each other and continued to flow through the column. In contrast, 2 or 3 sickled, rigid sRBC rarely negotiated the restriction but instead jammed together in the gap, thereby blocking the channel and initiating an upstream "logjam" of sRBC. The process was reversible upon switching over to oxygenated buffer, with complete resolution of the blockage as the sRBC regained their deformability.
As detailed above, our novel assay examines the ability of intact sRBC to traverse a tightly packed column of Sephacryl beads. When oxygenated, sRBC could pass easily through the column and form a visible red pellet at the bottom of polypropylene tubes or wells of the PCR plates. When deoxygenated and sickled, they were permanently trapped within the narrow channels between the beads, thus allowing the bottom of the tubes or the wells to retain the bright white color of the Sephacryl media. Thus, a red dot marks a hit. The endpoint of the assay can be obtained using high-resolution optical imaging (e.g., a commercially available document scanner); quantitative data analysis can be performed using simple image analysis routines. Reliable and reproducible readout was obtained over a wide range of Hct (2%-50%), MCV, MCHC, RDW values, and percentage HbF, suggesting that the use of blood from different donors should not significantly affect assay performance. In addition, HU therapy did not significantly affect the assay sensitivity.
Our preliminary studies confirmed that the assay reliably identifies molecules with antisickling properties. In vitro exposure to an effective antisickling agent allowed deoxygenated sRBC to remain flexible, pass through the Sephacryl column, and thus form a red pellet at the bottom of the wells. A clear negative result was observed for each molecule with deleterious effects on RBC (Figs. 4 and 5) . Owing to different methods for deoxygenation and assaying results (i.e., morphological evidence versus functional behavior as used herein), it is not possible to directly compare IC 50 values obtained in our study to literature levels. However, our value of 9 mM for potassium cyanate and aspartame (Fig. 5) is similar to these levels: 1) using potassium cyanate and deoxygenation at 30 mm Hg followed by formalin fixation, Cerami and Manning 5 indicate 18 mM; 2) using aspartame and deoxygenation with metabisulfate, Manion and others 10 report 3 to 6 mM. An important feature of this novel assay is that it uses an in vitro model that is relevant to the in vivo pathophysiology of SCD complications. 22, 23 Under normal circumstances, sRBC are not trapped in the microcirculation because the delay time between deoxygenation and sickling usually allows the cell to pass through the smaller vessels before the sickling process is completed. The development of vaso-occlusion is believed to be a 2-step process: 1) Adhesion of leukocytes or sRBC to the endothelium leads to partial vessel occlusion, and 2) the ensuing reduced flow rates allow sickling to occur, after which sickled RBC progressively pile up behind the initial obstruction. 26 The spontaneous occlusion of the narrow channels in our model system presumably occurs because the RBC are sickled and rigid before they enter the Sephacryl column, thus corresponding to the 2nd step of vaso-occlusion. This aspect of our assay is deemed very relevant because it is the 2nd step that is specific for SCD and is ultimately responsible for most complications of the disease.
CONCLUSION
The newly developed assay is simple, inexpensive, reproducible, requires no special reagents, has minimal SCD blood requirement, and should be readily adaptable to HTS. The use of intact erythrocytes combined with the Sephacryl gel bead system provides a more physiological testing environment than previous assays that examined only cell morphology or cellfree hemoglobin solutions. The successful development of a novel antisickling drug would have a tremendous impact on the management of individuals with SCD within the United States and worldwide and could dramatically improve the quality of life for millions of patients.
